"The wins we celebrated in 2022 further solidify our confidence in efruxifermin (EFX) as a potential best-in-class FGF21 analog addressing all core drivers of NASH disease progression," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "The statistically significant histology and secondary endpoint results from September’s topline HARMONY trial readout followed by EFX’s Breakthrough Therapy Designation in December further validate EFX’s potential to address high, global unmet need for patients living with NASH, and we look forward to reporting results from the SYMMETRY study in 2023."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKRO:
- Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- Morgan Stanley upgrades Akero Therapeutics into ‘multiple key catalysts’
- Akero Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Officer of Akero Therapeutics Yale sells $253K in company shares
